Search

Your search keyword '"Biasco, Guido"' showing total 886 results
Start Over Author "Biasco, Guido"
886 results on '"Biasco, Guido"'

51. sj-docx-1-pmj-10.1177_02692163211048340 ��� Supplemental material for An online international comparison of palliative care identification in primary care using the Surprise Question

Author

White, Nicola, Oostendorp, Linda JM, Vickerstaff, Victoria, Gerlach, Christina, Engels, Yvonne, Maessen, Maud, Tomlinson, Christopher, Wens, Johan, Leysen, Bert, Biasco, Guido, Zambrano, Sofia, Eychm��ller, Steffen, Avgerinou, Christina, Chattat, Rabih, Ottoboni, Giovanni, Veldhoven, Carel, and Stone, Patrick

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110308 Geriatrics and Gerontology
Abstract

Supplemental material, sj-docx-1-pmj-10.1177_02692163211048340 for An online international comparison of palliative care identification in primary care using the Surprise Question by Nicola White, Linda JM Oostendorp, Victoria Vickerstaff, Christina Gerlach, Yvonne Engels, Maud Maessen, Christopher Tomlinson, Johan Wens, Bert Leysen, Guido Biasco, Sofia Zambrano, Steffen Eychm��ller, Christina Avgerinou, Rabih Chattat, Giovanni Ottoboni, Carel Veldhoven and Patrick Stone in Palliative Medicine

Published
2021
Full Text
View/download PDF

69. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy

Author

Angelini, Sabrina, Pantaleo, Maria Abbondanza, Ravegnini, Gloria, Zenesini, Corrado, Cavrini, Giulia, Nannini, Margherita, Fumagalli, Elena, Palassini, Elena, Saponara, Maristella, Di Battista, Monica, Casali, Paolo G., Hrelia, Patrizia, Cantelli-Forti, Giorgio, and Biasco, Guido

Published
2013
Full Text
View/download PDF

71. An online international comparison of palliative care identification in primary care using the Surprise Question.

Author

White, Nicola, Oostendorp, Linda JM, Vickerstaff, Victoria, Gerlach, Christina, Engels, Yvonne, Maessen, Maud, Tomlinson, Christopher, Wens, Johan, Leysen, Bert, Biasco, Guido, Zambrano, Sofia, Eychmüller, Steffen, Avgerinou, Christina, Chattat, Rabih, Ottoboni, Giovanni, Veldhoven, Carel, and Stone, Patrick

Subjects
SURVIVAL, STATISTICS, LIFE expectancy, CROSS-sectional method, MULTIVARIATE analysis, PHYSICIANS' attitudes, REGRESSION analysis, PRIMARY health care, COMPARATIVE studies, CASE studies, PALLIATIVE treatment
Abstract

Background: The Surprise Question ('Would I be surprised if this patient died within 12 months?') identifies patients in the last year of life. It is unclear if 'surprised' means the same for each clinician, and whether their responses are internally consistent. Aim: To determine the consistency with which the Surprise Question is used. Design: A cross-sectional online study of participants located in Belgium, Germany, Italy, The Netherlands, Switzerland and UK. Participants completed 20 hypothetical patient summaries ('vignettes'). Primary outcome measure: continuous estimate of probability of death within 12 months (0% [certain survival]–100% [certain death]). A threshold (probability estimate above which Surprise Question responses were consistently 'no') and an inconsistency range (range of probability estimates where respondents vacillated between responses) were calculated. Univariable and multivariable linear regression explored differences in consistency. Trial registration: NCT03697213. Setting/participants: Registered General Practitioners (GPs). Of the 307 GPs who started the study, 250 completed 15 or more vignettes. Results: Participants had a consistency threshold of 49.8% (SD 22.7) and inconsistency range of 17% (SD 22.4). Italy had a significantly higher threshold than other countries (p = 0.002). There was also a difference in threshold levels depending on age of clinician, for every yearly increase, participants had a higher threshold. There was no difference in inconsistency between countries (p = 0.53). Conclusions: There is variation between clinicians regarding the use of the Surprise Question. Over half of GPs were not internally consistent in their responses to the Surprise Question. Future research with standardised terms and real patients is warranted. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

82. Additional file 2: of An online international comparison of thresholds for triggering a negative response to the â Surprise Questionâ : a study protocol

Author

White, Nicola, Oostendorp, Linda, Vickerstaff, Victoria, Gerlach, Christina, Engels, Yvonne, Maessen, Maud, Tomlinson, Christopher, Wens, Johan, Leysen, Bert, Biasco, Guido, Zambrano, Sofia, EychmĂźller, Steffen, Avgerinou, Christina, Chattat, Rabih, Ottoboni, Giovanni, Veldhoven, Carel, and Stone, Patrick

Abstract

Template for vignettes. (PDF 604 kb)

Published
2019
Full Text
View/download PDF

83. Additional file 1: of An online international comparison of thresholds for triggering a negative response to the â Surprise Questionâ : a study protocol

Author

White, Nicola, Oostendorp, Linda, Vickerstaff, Victoria, Gerlach, Christina, Engels, Yvonne, Maessen, Maud, Tomlinson, Christopher, Wens, Johan, Leysen, Bert, Biasco, Guido, Zambrano, Sofia, EychmĂźller, Steffen, Avgerinou, Christina, Chattat, Rabih, Ottoboni, Giovanni, Veldhoven, Carel, and Stone, Patrick

Abstract

SPIRIT checklist. (PDF 172 kb)

Published
2019
Full Text
View/download PDF

89. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

Author

Bajetta, Emilio, Bartolomeo, Maria Di, Mariani, Luigi, Cassata, Antonio, Artale, Salvatore, Frustaci, Sergio, Pinotti, Graziella, Bonetti, Andrea, Carreca, Ignazio, Biasco, Guido, Bonaglia, Luigi, Marini, Giovanni, Lannelli, Antonio, Cortinovis, Diego, Ferrario, Ermina, Beretta, Elena, Lambiase, Antonio, and Buzzoni, Roberto

Subjects
Colorectal cancer -- Care and treatment, Capecitabine -- Dosage and administration, Health
Published
2004

90. TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS

Author

Grassi Elisa, Durante Sandra, Astolfi Annalisa, FREIER, EVA, Comito Francesca, Frega Giorgio, Palloni Andrea, Panzacchi Riccardo, Santini Donatella, Falconi Mirella, Teti Gabriella, Serravalle Salvatore, Casadei Riccardo, Ricci Claudio, Biasco Guido, Di Marco Mariacristina, and Grassi Elisa, Durante Sandra, Astolfi Annalisa, Eva Freier, Comito Francesca, Frega Giorgio, Palloni Andrea, Panzacchi Riccardo, Santini Donatella, Falconi Mirella, Teti Gabriella, Serravalle Salvatore, Casadei Riccardo , Ricci Claudio, Biasco Guido, Di Marco Mariacristina

Subjects
endocrine system diseases, Intraductal papillary mucinous neoplasm, cystic precancerous lesion
Abstract

Introduction. Intraductal papillary mucinous neoplasm (IPMN) is the most common cystic precancerous lesion of pancreatic cancer (PDA). IPMNs can progress from low to high-grade dysplasia, to invasive PDAC, but exact data regarding cancer risks are limited. PDAC is the fourth leading cause of cancer death . The overall 5-year survival is 6%, but survival of patients with early stage PDAC is significantly better. AIM We used an approach coupling high resolution cytogenetic analysis (Affymetrix Oncoscan FFPE Array) with a clinically-oriented bioinformatic interpretation of data to understand what are the most relevant pathways altered in precursor lesions. Materials and methods High resolution cytogenetic analysis was performed in 20 formalin fixed paraffin embedded samples of IPMNs by Oncoscan FFPE assay. Genomic data were analyzed for copy number gains and losses, loss of heterozygosity and for a panel of recurrent somatic mutations. Results were validated by qPCR and FISH analysis. Results Twenty samples, including 14 mixed-type IPMNs (70%), 4 branch-duct IPMNs (20%) and 2 main-duct IPMNs (10%), were collected. We identified micro-invasive carcinoma (< 1 mm) and invasive carcinoma in 25% and in 10% of IPMNs respectively. By our high resolution cytogenetic analysis we observed that 8 IPMNs (40%) presented a nearly normal karyotype (< 4 copy number alterations), while 12 IPMNs (60%) showed a complex karyotype (> 10 alterations). In the latter subgroup were detected specific copy number gains of TERC and c-MYC oncogenes. Interestingly we noticed that TERC and c-MYC overexpression, present in 92% and 45% of complex karyotype samples respectively, were only observed in high-grade IPMNs, suggesting a possible role in a progression to malignancy. Oncoscan data were confirmed by Real Time and FISH analysis. Conclusions Those results suggest a role of TERC and c-MYC overexpression as a possible biomarkers in the early identification of patients with complex karyotype IPMNs in order to better stratification of cystic lesions that could require surgery

Published
2017

97. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib

Author

Pantaleo Maria, Mandrioli Anna, Saponara Maristella, Nannini Margherita, Erente Giovanna, Lolli Cristian, and Biasco Guido

Subjects
Sorafenib, renal cell carcinoma, coronary syndrome, cardiotoxicity, cardiac ischemia/infarction, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Tyrosine kinase inhibitors (TKIs) are currently approved for the treatment of metastatic renal cell carcinoma (mRCC). The cardiotoxic effects of sorafenib and sunitinib may cause hypertension, left ventricular ejection fraction (LVEF) dysfunction and/or congestive heart failure (CHF), and arterial thrombo-embolic events (ATE). Only three cases of coronary artery disease related to sorafenib therapy have been described in the literature, and all were due to arterial vasospasm without evidence of coronary artery stenosis on angiography. Cardiotoxicity is commonly associated with the presence of cardiovascular risk factors, such as a history of hypertension or coronary artery disease. Case presentation We describe a patient who experienced an unusual cardiac event after 2 years of sorafenib treatment. A 58-year-old man with mRCC developed acute coronary syndrome (ischemia/infarction) associated with critical sub-occlusion of the common trunk of the left coronary artery and some of its branches, which was documented on coronary angiography. The patient underwent triple coronary artery bypass surgery, and sorafenib treatment was discontinued. He did not have any cardiovascular risk factors, and his cardiac function and morphology were normal prior to sorafenib treatment. Conclusions Further investigation of a larger patient population is needed to better understand cardiac damage due to TKI treatment. Understanding the usefulness of careful cardiovascular monitoring might be important for the prevention of fatal cardiovascular events, and to avoid discontinuation of therapy for the underlying cancer.

Published
2012
Full Text
View/download PDF

99. The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting

Author

Nannini Margherita, Pantaleo Maria A, Maleddu Alessandra, and Biasco Guido

Subjects
Medicine
Abstract

Abstract Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Most GIST harbor a mutation affecting either the KIT or PDGFRA genes, whereas a small subgroup of tumors is wild type for mutations. Mutation of tyrosine kinase receptors is a mechanism of drug resistance that can occur either at the beginning of treatment (primary resistance) or during the course of therapy (secondary resistance). In addition, mutational status can predict the response to treatment with tyrosine kinase inhibitors, but the role of mutational status as a prognostic factor remains controversial. Evidence of a potential role of mutational status as a prognostic factor has emerged over the past decade. The presence of KIT exon 11 insertion/deletion involving either one or both Trp557-Lys558 amino acids correlates with a poorer clinical outcome if compared to patients with tumors wild type for KIT exon 11 mutations. A malignant clinical behavior has also been documented for KIT exon 13 and KIT exon 9 mutant GIST. Patients with GIST harboring a PDGFRA mutation seem to have a better prognosis than the others. The aim of this paper is to review the clinical significance of tyrosine kinase mutational status.

Published
2011
Full Text
View/download PDF

100. How Do Experienced Professors Teach Palliative Medicine in European Universities? A Cross-Case Analysis of Eight Undergraduate Educational Programs

Author

Noguera, Antonio, primary, Bolognesi, Deborah, additional, Garralda, Eduardo, additional, Beccaro, Monica, additional, Kotlinska-Lemieszek, Aleksandra, additional, Furst, Carl Johan, additional, Ellershaw, John, additional, Elsner, Frank, additional, Csikos, Agnes, additional, Filbet, Marilene, additional, Biasco, Guido, additional, and Centeno, Carlos, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results